Collectively, our findings re‐emphasize the biologic importance that optimal adherence could have on maximizing the therapeutic benefit of ART, even in individuals who start ART with high CD4+ T cells, in whom advanced immunodeficiency has not been established 34. This evidence concerns the gene CD4 and immunodeficiency disease.